Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $733.000 thousand which beat the analyst consensus estimate of $30.000 thousand by 2.34K percent. This is a 88.31 percent decrease over sales of $6.272 million the same period last year.